गॉलब्लैडर कैंसर

Evidence suggests distinct models of molecular and pathologic progression, and a growing body of genetics data points to a heterogeneous collection of underlying mutations in key oncogenes and tumor suppressor genes. Although tumor genetics have been used to tailor individual treatment regimens and guide clinical decision making in other cancers, these principles have not been applied in gallbladder malignancy. Recent clinical trials with targeted therapies seem promising, although the relationships between subsets of patients with positive responses to therapy and tumor genetics remain unexpl…

Sponsor: Banaras Hindu University
NCT05404347 on ClinicalTrials.gov
Last updated on the registry 13 Aug 2024 · read by us 20 Oct 2026